Clinical Observation Of Butylphthalide Soft Capsules In Treatment Of Vascular Cognitive Impairment Non-dementia

Objective:To explore the therapeutic effect of butylphthalide soft capsules on patients with vascular cognitive impairment in non-demented type(VCIND),and provide an important reference basis for promoting the rehabilitation of VCIND patients..Methods:Eighty patients with cerebral infarction who were hospitalized in the Department of Neurology of the People’s Hospital of Guangxi Zhuang Autonomous Region from May 2018 to May 2019 were selected as subjects.All patients met the diagnostic criteria for cerebral infarction.The random number table method was divided into a control group and an observation group.40 cases each.The control group was given piracetam capsules and antiplatelet,hypolipidemic and other conventional treatments.The observation group patients were given butylphthalide soft capsules on the basis of conventional treatments.The course of treatment was 3 months.For the two groups of patients before treatment,1 and 3 months after treatment,the clinical simple intelligent mental state examination scale(MMSE),the Montreal Cognitive Assessment Scale(Mo CA),the daily living ability scale(ADL),and EEG Improve the situation and compare the changes in serum Bu Ch E content,and observe the clinical efficacy of butylphthalide soft capsules in the treatment of VCIND.Results:After 1 month of treatment,the EEG of 16 patients(40%)in the observation group was improved,while the EEG of the control group was not significantly improved,the difference was statistically significant(P<0.05).After 3 months of treatment,In the observation group,24 patients(60%)had improved EEG,while in the control group,2 patients(5%)had improved EEG.The difference was statistically significant(P<0.05).The MMSE score and MOCA score of the observation group were significantly higher than those of the control group 1 and 3 months after treatment.The observation group’s cognitive impairment from language,山attention,computing power,delayed memory,and immediate memory was improved compared with the control group.Significantly(P<0.05).The ADL scores of the observation group were significantly higher than those of the control group 1 and 3 months after treatment.Patients in the observation group improved significantly from the control group in terms of physical self-care ability and instrumental daily living ability(P<0.05).The serum BuChE content of the observation group patients after 1 month of treatment decreased compared with before treatment,and the decline was more obvious after 3 months of treatment,which was significantly lower than that of the control group(P<0.05).The serum Bu Ch E content was negatively correlated with MMSE score(r=-0.54,P<0.05);the serum Bu Ch E content was negatively correlated with MOCA score(r=-0.48,P<0.05);the patient’s serum Bu Ch E content was correlated with ADL score Negative correlation(r=-0.66,P<0.05)..Conclusion:1.Butylphthalide soft capsules have a significant therapeutic effect on VCIND patients,can improve the degree of cognitive impairment of VCIND patients,improve patients’ self-care ability,and are safe and well tolerated.It is an effective drug for the treatment of VCIND patients.Certain clinical application value.2.Butylphthalide soft capsules for VCIND patients can obtain higher shortterm effects,but the clinical course of medication should be as long as possible for more than 1 month to obtain the best drug cycle.3.There is a correlation between serum Bu Ch E content and the degree of cognitive impairment in VCIND patients,which can reflect and predict the treatment effect and prognosis of VCIND patients,and can guide clinical treatment.